Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management (Q36937820)

17 August 2017

1 reference

title

Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management (English)

1 reference

17 August 2017

1 reference

Crepaldi G

1

1 reference

17 August 2017

Carruba M

2

1 reference

17 August 2017

Comaschi M

3

1 reference

17 August 2017

Del Prato S

4

1 reference

17 August 2017

Frajese G

5

1 reference

17 August 2017

Paolisso G

6

1 reference

17 August 2017

1 July 2007

1 reference

Journal of Endocrinological Investigation

17 August 2017

1 reference

17 August 2017

30

1 reference

17 August 2017

610-614

1 reference

17 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03346357

17 August 2017

0 references

cites work

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Type 2 diabetes, insulin secretion and beta-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03346357

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17848846

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/BF03346357

1 reference

17 August 2017

1 reference